Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 in Non-diabetic Overweight or Obesity
NCT06226090Phase 2Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Feb 2024
- Primary completion
- Sep 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GX-G6 in obesity and Overweight (6 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Percentage relative change from baseline in body weight at 24 weeks. Started Feb 2024; status: completed.
02
Drugs
GX-G6
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06226090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226090.